drugset / Trial / NCT02273661

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

NCT02273661

Phase 2 Completed 174 enrolled Poitiers University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy.

Timeline

Start
2014-11-19
Primary completion
2019-06-28
Completion
2019-06-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 25 mg Other